Drug intelligence / Profile preview

interferon alfa-2a + doxorubicin + bleomycin + vinblastine + dacarbazine

Development stage: Unknown
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Intravenous

Overview

This combination therapy regimen consists of the immunomodulatory cytokine interferon alfa-2a added to the standard ABVD chemotherapy protocol, which includes doxorubicin (Adriamycin), bleomycin, vinblastine (Velban), and dacarbazine. Investigated by the M.D. Anderson Cancer Center in a Phase II clinical trial (NCT01404936), the regimen was designed for patients with relapsed or advanced untreated Hodgkin lymphoma. The rationale for adding interferon alfa-2a is to leverage its immunomodulatory and antiproliferative properties to enhance the anti-tumor immune response against Hodgkin's disease. Interferon alfa-2a is a recombinant protein that binds to type I interferon receptors (IFNAR1 and IFNAR2), while the ABVD components provide multi-targeted cytotoxic effects through DNA intercalation, DNA alkylation, DNA cleavage, and microtubule inhibition.

Brand names: Roferon-AAdriamycinBlenoxaneVelbanDTIC-Dome
Other names: interferon-2a-M.D. Anderson Cancer Center-Hodgkin lymphomainterferon2a-M.D. Anderson Cancer Center-Hodgkin lymphomainterferon 2a-M.D. Anderson Cancer Center-Hodgkin lymphomainterferon alfa-2a + ABVDIFN + ABVDinterferon-2a + ABVDIFN-alfa-2a + ABVD

Targets

TOP2A (DNA topoisomerase II)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on interferon alfa-2a + doxorubicin + bleomycin + vinblastine + dacarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alfa-2a + doxorubicin + bleomycin + vinblastine + dacarbazine.

Explore the full profile